Company Description
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases.
It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-α receptor agonist targeting HBV and HDV.
The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Dec 17, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Jason Okazaki |
Contact Details
Address: Two Tower Place, 7th Floor South San Francisco, California 94080 United States | |
| Phone | 833 509 4583 |
| Website | assemblybio.com |
Stock Details
| Ticker Symbol | ASMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001426800 |
| CUSIP Number | 045396108 |
| ISIN Number | US0453962070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jason A. Okazaki | Chief Executive Officer, President and Director |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
| Dr. Uri A. Lopatin M.D. | Co-Founder and Clinical and Scientific Advisor |
| Dr. Adam Zlotnick | Co-Founder, Chief Scientific Advisor and Chair of Hbv and Virology Science Advisory Board |
| Jeanette M Bjorkquist | Executive Director of Accounting and Treasury |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer |
| Thomas E. Rollins | Executive Officer |
| Amy Figueroa C.F.A. | Investor Relations Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 424B5 | Filing |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |